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Abstract.  Lipid bodies, nonmembrane-bound cyto- 
plasmic inclusions, serve as repositories of esterified 
arachidonate and are increased in cells associated with 
inflammatory reactions. We have evaluated stimuli and 
mechanisms responsible for lipid body formation 
within human polymorphonuclear leukocytes (PMNs). 
Arachidonic acid and oleic acid stimulated dose- 
dependent formation of lipid bodies over 0.5-1 h. 
Other C20 and C18 fatty acids were less active and 
demonstrated rank orders as follows: cis-unsaturated 
fatty acids were much more active than trans-fatty 
acids, and activity diminished with decreasing num- 
bers of double bonds. Lipid bodies elicited in vitro 
with cis-fatty  acids were ultrastructurally identical to 
lipid bodies present in PMNs in vivo.  Lipid body in- 
duction was not because of fatty acid-elicited oxidants 
or fatty acid-induced ATP depletion. Cis-fatty acid- 
induced activation of protein kinase C (PKC) was in- 
volved in lipid body formation as evidenced by the ca- 
pacity of other PKC activators,  1-oleoyl-2-acetyl- 
glycerol and two active phorbol esters, phorbol 
myristate acetate, and phorbol  12,13 dibutyrate, but 
not an inactive phorbol, to induce lipid body forma- 
tion. The PKC inhibitor,  1-O-hexadecyl-2-O-methyl- 
glycerol, inhibited PMN lipid body formation induced 
by oleic and arachidonic acids and by 1-oleoyl-2-acetyl- 
glycerol and phorbol myristate acetate. Other PKC in- 
hibitors (staurosporine, H-7) also inhibited lipid body 
formation. Formation of lipid bodies in PMNs is a 
specific cellular response, stimulated by cis-fatty  acids 
and diglycerides and apparently mediated by PKC, 
which results in the mobilization and deposition of 
lipids within discrete, ultrastructuraUy defined cyto- 
plasmic domains. 
zPID bodies are nonmembrane bound, cytoplasmic in- 
clusions present within neutrophilic (49) and eosino- 
philic  (48) leukocytes,  fibroblasts  (52),  endothelial 
cells (23), and other cell types (23). The genesis and func- 
tions of lipid bodies are largely unknown in most cells. In 
both neutrophils  (polymorphonuclear leukocytes;  PMNs) L 
(49) and eosinophils (48), lipid bodies become more promi- 
nent in number and size when these leukocytes are engaged 
in inflammatory responses. Increased numbers of lipid bod- 
ies in human PMNs associated with various infectious, neo- 
plastic, and other inflammatory reactions have been demon- 
strated both within biopsied tissues and in PMNs from blood 
and exudative effusions (13, 49). In addition, PMNs from ex- 
perimentaUy elicited peritoneal exudates in rabbits, but not 
PMNs collected concurrently from rabbit peripheral blood, 
contained increased numbers of lipid bodies (36). These in 
vivo findings with human and rabbit  PMNs indicated that 
1. Abbreviations  used in this paper: BHT, butylated hydroxytoluene; fMLE 
N-formyl-methionyl-leucyl-phenylalanine;  HMG, 1-O-hexadecyl-2-O-methyl- 
rac-glyeerol;  PDBu, phorbol  12,13 dibutyrate;  PDD, 40t-phorbol 12,13 
dideeanoate; PKC, protein kinase C; PMA, phorbol 12-myristate 13-ace- 
tate; PMNs, polymorphonuclear leukocytes (neutrophils); OAG, 1-oleoyl- 
2-acetyl-rac-glycerol; 2,4 DNP, 2,4 dinitrophenol. 
lipid  body formation  was a morphologic correlate of the 
cells' participation  in inflammation.  It is PMNs in sites of 
inflammation, not normal blood PMNs, that are likely to be 
subjected to activating cellular ligands and lipids and to be 
engaged in stimulated cellular responses,  including eicosa- 
noid synthesis and release.  Whether lipid body formation 
represents  a  toxic sequela  or a  specific  response  within 
PMNs has not been defined; and mechanisms responsible for 
lipid body formation in leukocytes or other cell types have 
not been identified (36). 
Although the composition and functions of lipid bodies in 
leukocytes remain uncertain, a role for lipid bodies as major 
intracellular sites of deposition of fatty acids, including ara- 
chidonic acid, has been indicated by electron microscopic 
autoradiography (18, 19, 23, 48, 49).  In human PMNs (49) 
and eosinophils (48), lipid bodies were the predominant sites 
of localization  of cell-incorporated, esterified  [3H]-arachi- 
donate (49).  Other pH]-fatty acids also localized to PMN 
lipid bodies  (49).  Similarly,  incorporation  of [3H]-arachi- 
donate into lipid bodies of  human alveolar macrophages and 
mast cells  (18, 19) and murine and guinea pig peritoneal 
macrophages  (18) has been demonstrated. 
Since lipid bodies in leukocytes can serve as stores of es- 
terified  arachidonate  and increase in number when these 
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tigated stimuli and mechanisms which lead to lipid body for- 
mation in PMNs. We have found that induction of lipid body 
formation  is  mediated  by  activation  of protein  kinase  C 
(PKC) and can be elicited preferentially by cis-unsaturated 
fatty acids, which can activate PKC (15, 29, 30), and by other 
PKC  activators,  1-oleoyl-2-acetyl-rac-glycerol (OAG)  and 
specific phorbol esters (10, 22, 32). PKC activation in PMNs 
elicits multiple alterations in lipid metabolism, including in- 
creases in classes ofdiglycerides (1, 16, 35, 47) and phospho- 
lipids (28, 41, 46) and priming for stimulated release of ei- 
cosanoids (27,  28).  In the context of these PKC-mediated 
biochemical changes in lipids, PKC activation also promotes 
the mobilization and deposition of lipids into discrete cyto- 
plasmic  inclusions.  In  combination  with observations that 
lipid bodies are a potential intracellular source of esterified 
arachidonate,  these  findings  suggest  that  lipid  bodies  in 
PMNs may have a role in eicosanoid production by these 
cells. 
Materials and Methods 
Materials 
Fatty acids and their analogs were obtained from Sigma Chemical Co. (St. 
Louis, MO) or NuChek Prep (Elysian, MN). Thioearbohydrazide,  phorbol 
12-myristate  13-acetate  (PMA),  4t~-phorbol  12,13  didecanoate  (PDD), 
phorbol 12,13 dibutyrate (PDBu), dipalmitin, diolein,  l-oleoyt-2-acetyl- 
mc-glycerol  (OAG),  lysopalmitoylphosphatidylcholine,  phosphatidylser- 
ine, phenylmethylsnifonyl  fluoride,  bovine erythrocyte superoxide  dismu- 
tase (3,000 U/rag), bovine liver catalase (11,000 U/rag), 2,4 dinitrophenol 
(2,4 DNP), butylated hydroxytoluene  (BHT) (Sigma Chemical, St. Louis, 
MO); Ficoll-Hypaque,  6% dextran in normal saline (Maerodex;  Pharma- 
cia, Piscataway,  NJ); osmium tetroxide  (Electron Microscopy  Sciences, 
Fort Washington, PA); Bloom's gelatin, isopropanol,  oil red O, (Fisher, Med- 
ford, MA); staurosporine (Kamiya Biomedical Co., Thousand Oaks, CA); 
valinomycin, H-7 (1-[5-isoquinolinesulfonyl]-2-methyl-piperazine)  (Calbio- 
them,  San Diego,  CA);  1-O-hexadecyl-2-O-methyl-rac-glycerol (HMG) 
(Bachem Biochemicals,  Philadelphia, PA); and HBSS (Microbiological  As- 
sociates,  Walkersville,  MD) were obtained as indicated. 
PMN Purification and Lipid Body Induction 
Peripheral blood from normal donors was anticoagulated  with acidified ci- 
trate; erythrocytes  were removed by dextran sedimentation; and granulo- 
cytes (>95 % PMNs, remainder eosinophils) were collected after centrifu- 
gation  on Ficoll-Hypaque  (49)  and washed  in calcium, magnesium-free 
HBSS. Residual erythrecytes were lysed with hypotohic saline, and PMNs 
were resuspended in calcium, magnesium-free Tyrode's buffer (0.1% wt/vol) 
dextrose,  0.1% NaHCOs,  0.02% KC1, 0.8% NaC1, 0.005% NaH2POa, pH 
7.5) with 0.1% gelatin. Incubations were done with gelatin and not albumin 
to minimize protein binding of fatty acids and were done without exogenous 
calcium to avoid effects of calcium on the solubility or membrane partition- 
ing of fatty acids (45).  In representative experiments,  cell viability was 
checked with trypan blue staining, and for each of the fatty acids was >90%. 
PMNs (10~/ml in 3 ml) were incubated at 37°C for 60 rain, a time which 
yielded near maximal lipid body formation for both arachidonic and oleic 
(49) acids. To minimize toxicity to cells, incubations with PMA or with in- 
hibitors of PKC were limited to 30 min; and with PKC inhibitors, stimulat- 
ing fatty acids and OAG were used at submaximal (2.5 #M) concentrations. 
Possible cytotoxicity  was also assessed by evaluating morphology of fixed 
PMNs during lipid body counting.  Fatty acids, diacylglycerides,  and lyso- 
phosphatidylcholine,  dissolved in ethanol, were used at a final 0.1% ethanol 
concentration. Control cells were incubated likewise in 0.1% ethanol. Within 
all experiments,  incubations with 1 or 2.5 #M oleic acid were included as 
positive control conditions for PMN lipid body formation.  Phorbol esters, 
HMG, valinomycin,  and staurosporine were dissolved  in dimethylsulfox- 
ide; control cells were incubated in 0.1% dimethylsulfoxide.  H-7 was dis- 
solved as a stock solution in distilled water. HMG, staurosporine,  and H-7 
were added ptewarmed at 370C to 37°C prewarmed PMNs for 15 rain before 
adding fatty acids or other stimuli. Superoxide dismutase and catalase solu- 
tions were heat inactivated  for 15 rain in boiling water. 
Lipid Body Staining and Enumeration 
PMNs ('~5 ×  104) were cytocentrifuged  (Cytocentfifuge,  Shandon, Pitts- 
burgh, PA) (1,000 RPM, 5 rain) onto glass slides. In early studies,  slides, 
while still moist, were fixed by exposure to OsO4 vapors, and then stained 
for 2-4 h in oil red O (6 parts 0.5%  [wt/vol] oil red O in isopropanol,  4 
parts water), rinsed briefly in isopropanol,  and then mounted with Apathy's 
medium. In later studies, greater contrast of lipid bodies was obtained by 
staining slides  sequentially  with ferrocyanide-reduced  OsO4,  thiocarbo- 
hydrazide  and OsO4 (53).  Slides  were  fixed in 3.0% glutaraldehyde  in 
0.1 M cacodylate buffer, pH 7.4 (15 rain), rinsed twice in cacodylate buffer 
(3  rain),  stained in  1.5% K4Fe(CN)6 in 1.0% aqueous  OsO4 (30 min), 
rinsed three times in water, immersed in 1.0% thiocarbohydrazide  (5 min), 
rinsed three times in water,  restained in 1.0% OsO4 in 0.1 M cacodylate 
(3 min), rinsed with water, and then dried and mounted in Apathy's me- 
dium. The morphology  of fixed cells was observed, and lipid bodies were 
enumerated with phase contrast microscopy, and a 100× objective lens in 
25-50 consecutively  scanned PMNs;  any eosinophils were not counted. 
Results were calculated as mean (+SEM) lipid bodiesdPMN or as mean net 
(:I:SEM) lipid bodies/PMN, after subtracting the lipid bodies/PMN formed 
during control incubations. 
EM of  PMN Lipid Bodies 
Ceils for EM were processed and examined as previously detailed (17, 49). 
PMNs were fixed in 2% paraformaldehyde,  2.5% ghitaraldehyde,  0.025% 
CaC12 in 0.1 M sodium cacodylate buffer, pH 7.4 for 1 h, washed in cold 
0.1 M cacodylate buffer, and rapidly centrifuged  through molten agar. The 
cell  pellets  in agar were  postfixed  in S-collidine-buffered  osmium and 
stained en bloc with uranyl acetate before dehydration in a graded series 
of alcohols and embedding in a propylene oxide-Epon  sequence.  Thin sec- 
tions were stained with lead citrate and examined in an electron microscope 
(Model  400; Philips Electronic  Instruments, Inc., Mahwah,  NJ). 
PKC Assays 
PKC activity in cytosolic fractions of PMNs was assayed by quantitating 
phosphorylation of a synthetic PKC substrate peptide  (PKC assay system; 
Amersham Corp., Arlington Heights, IL). After hypotonic erythrocyte  ly- 
sis,  PMNs,  purified  as described above,  were  washed  with HBSS  and 
resuspended  at 5  x  107/ml in 50 mM Tris-HC1, pH 7.5, 2 mM EGTA, 50 
mM 2-mercaptoethanol, and 1 mM phenylmethylsulfonyl  fluoride.  PMNs 
were disrupted  using an ice-cold homogenizer with multiple passes to 
achieve ,x,75 % cell breakage; and cytosol was recovered after centrifugation 
(150,000 g for 90 mins, 4°C). Assays were performed as specified by the 
manufacturer except that phosphatidylserine and diolein were substituted 
for the supplied lipid mixture.  The standard assay mixture contained 25 #1 
cytosolic fractions, 2 #1 without or with either HMG (in varying concentra- 
tions), 50/zM H-7 or 50 #M stanrosporine, 2 #1 2 #g/ml diolein, and 25 
tA 12 mM calcium acetate, 30 mM dithiothreitol, 900 #M PKC substrate 
peptide in 50 mM Tris-HCl, pH 7.5, with 0.05 % sodium azide and 20 #g/ml 
phosphatidylserine.  Reactions were started by adding 25 #1 of magnesium 
ATP buffer (150 #M ATP, 45 mM magnesium acetate,  10 #Ci/ml s2p_),_ 
ATP (3,000 Ci/mmol, Amersham Corp.), in 50 mM Tris-HC1, pH 7.5), in- 
cubated for 15 min at 25"C, and then stopped with acidic reaction-quench- 
ing  reagent.  Phosphorylated substrate was  trapped  on peptide-binding 
paper,  washed with acetic acid,  and counted by liquid scintillation spec- 
trometry. Assays were done within conditions of linearity for time and pro- 
tein. In repeated  experiments  measured PKC activity was >94% calcium 
and phospholipid dependent (assessed in 12 rnM EGTA without added dio- 
lein, phosphatidylserine,  and calcium) and ranged •0.15  nmol phosphate 
incorporated/rain/rag protein. Results are derived from means of triplicate 
or quadruplicate assays for each condition. 
Results 
Lipid Body Induction by Fatty Acids 
PMNs purified from peripheral blood of normal donors con- 
tained few lipid bodies (Fig. 1 A), an average of 0.7 lipid bod- 
ies/PMN  (mean  for 500  PMNs  from  20  leukocyte  isola- 
The Journal of Cell Biology, Volume 113, 1991  138 Figure 1. Unstimulated (,4) and OAG-stimulated  (B) PMNs stained with reduced osmium-thiocarbohydrazide-osmium  to show cytoplasmic 
lipid bodies. PMNs were incubated for 60 rain with control 0.1% ethanol (.4) or 10 #M OAG (1-oleoyl-2-acetyl-rac-glycerol)  (B). In A, 
lipid bodies are noted with an-ows; in B, multiple darkly stained lipid bodies are present within each PMN. Bars,  10/~m. 
tions).  Since PMNs incubated with oleic acid had rapidly 
formed new lipid bodies over 30-60 rain (49),  we inves- 
tigated lipid body formation in PMNs incubated with fatty 
acids of  varying structures. Arachidonic and oleic acids were 
about equipotent in  eliciting  dose-dependent increases  in 
lipid body formation, but the methyl esters of these fatty 
acids and arachidonyl alcohol were ineffective (Fig. 2). The 
morphology of lipid bodies elicited in vitro in PMNs  in- 
cubated with these fatty acids was ultrastructurally identical 
(Fig. 3), including size range, consistency and electron den- 
sity after osmium fixation, to native lipid bodies formed in 
vivo in blood and tissue PMNs (49). In addition, lipid bodies 
in PMNs exposed to oleic and arachidonic acids had an iden- 
tical investiture, not with a defined unit membrane, but with 
an electron dense, peripheral lipid body "shell" partially or 
fully around their circumference (Fig.  3 B), as also found 
on PMN lipid bodies in vivo (49). 
Induction of lipid body formation by other fatty acids with 
different degrees of unsaturation and double-bond geome- 
tries was examined. With 20 carbon fatty acids (Fig. 4 A), 
potency for lipid body induction  increased progressively 
with the number of cis double bonds in the fatty acid. At 10 
#M fatty acid, the rank order for lipid body induction was 
arachidonic acid (eicosatetraenoic acid,  C20:4,  cis 5,8,11, 
14) -  homo-3,-linoleic acid (eicosatrienoic acid, C20:3, cis 
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Figure 2.  Lipid bodies in PMNs incubated for 60 rain with C20 
fatty acids (A) and C18 fatty acids (B) and their analogs. C20 fatty 
acids (A) include arachidonic acid (B), arachidonyl alcohol (A), 
and arachidonyl methylester (e); C18 fatty acids (B) include oleic 
acid (o) and oleoyl methylester (D). Mean net lipid bodies/PMN 
in 25-50 cells are corrected for lipid bodies (usually 1-3/PMN) in 
PMNs incubated in 0.1% ethanol alone. For arachidonic and oleic 
acids and arachidonyl methylester, results are means (+SEM) of 
six, eight and two experiments, respectively. 
Weller et al. PMN 1_z'pid Body Formation and Protein Kinase C  139 Figure 3.  Electron micrographs of oleic acid-induced lipid bodies in PMNs. PMNs incubated for 60 min with 5 #M oleic acid (A) or 
1 #M oleic acid (B) show cytoplasmic lipid bodies (arrowheads)  which in B are partially invested with more electron dense lamellae, 
or a "shell." Bars, (A) 1 #m; (B) 0.2/zm. 
8,11,14) > eicosadienoic acid (C20:2, cis 11,14) > eicosenoic 
acid (C20:1, cis 11) >  eicosadienoic acid (C20:2, trans  11, 
14) >  eicosenoic acid (C20:1,  trans  11) >  eicosanoic acid 
(C20:0). The rank order with increasing degrees of unsatu- 
ration was also evident with 18 carbon fatty acids (Fig. 4 B), 
as was the importance of  the geometry of  double bonds. With 
10 #M fatty acid, potency for lipid body induction was oleic 
acid (C18:1,  cis 9) >  ~,-linoleic  acid (C18:3,  cis 6,9,12)  > 
linoleic acid C18:2, cis 9,12) > linoleidic acid (C18:2, trans 
9,12) >  elaidic acid (C18:1,  trans 9) >  stearic acid (C18:0). 
Effects of unsaturated  fatty acids  were additive.  Whereas 
PMNs incubated alone with 1 #M oleic acid or 1 or 2.5 #M 
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Figure 4. Induction of PMN lipid body formation by C20 
fatty acids (A) and C18 fatty acids (B). C20 fatty acids 
included arachidonic acid (eicosatetraenoic acid, C20:4, 
cis 5,8,11,14), homo-3,-linoleic  acid (eicosatrienoic acid, 
C20:3, cis 8,11,14), eicosadienoic acid (C20:2, cis  11, 
14), eicosenoic acid (C20:1, cis 11), eicosadienoic acid 
(C20:2, trans 11,14), eicosenoic acid (C20:1, trans 11), 
and eicosanoic acid (C20:0). C18 fatty acids included 
oleic acid (C18:1, cis 9), y-linoleic acid (C18:3, cis 6, 
9,12), linoleic acid  (C18:2,  cis  9,12), linoleidic acid 
(C18:2, trans 9,12), elaidic acid (C18:1, trans 9), and 
stearic acid (C18:0). Mean lipid bodies/PMN in 25-50 
cells were corrected for lipid bodies (between 1-4/PMN) 
in PMNs incubated with control 0.1% ethanol. Results 
are means from six experiments with arachidonic acid, 
from two each with 11,14 trans-eicosadienoic, 11 trans- 
eicosenoic, and eicosanoic acids, from eight with oleic 
acid and three with linoleic acid. 
arachidonic acid contained I0.4 +  3.2 (+SEM), 9.9 +  3.5 
and 17.3  +  4.3 lipid bodies/PMN, respectively, combina- 
tions of 1/~M oleic acid with 1 or 2.5/~M arachidonic acid 
yielded 16.6 +  4.8 and 27.7 +  7.0 lipid bodies/PMN. In con- 
trast to cis-unsaturated fatty acids, the fully saturated fatty 
acids, palmitic (C16:0)  and myristic (C14:0), two diglycer- 
ides, dipalmitin and diolein, and lysophosphatidylcholine, at 
concentrations up to 10/~M, failed to induce lipid body for- 
mation (data not shown). 
Mechanism of Lipid Body lnducaon 
Since lipid body formation was not elicited simply by ex- 
posures to exogenous lipids but was structurally dependent 
on the composition and stereochemistry of stimulating fatty 
acids, potential mechanisms of lipid body formation were 
sought from the recognized effects of fatty acids, especially 
cis-unsaturated fatty acids, on PMNs. 
Potential Toxic Effects of cis-Fatty Acids. Focal cytoplas- 
mic accumulations of lipids might have developed as adverse 
consequences of fatty acid-stimulated metabolic events in 
PMNs.  Specific  fatty acids,  notably cis-unsaturated  fatty 
acids, stimulate the respiratory burst of PMNs (4, 5), and 
the potencies of various polyunsaturated fatty acids as stim- 
uli for PMN superoxide anion release (4, 5) were approxi- 
mately the same for lipid body induction. To evaluate whether 
fatty acid-elicited superoxide anion or H20~ contributed to 
lipid body formation,  superoxide  dismutase and catalase 
were added during incubations of PMNs with oleic acid. 
These enzymes, in amounts sufficient  to consume superoxide 
anion or H202 released by stimulated PMNs, did not inhibit 
oleic acid-induced lipid body formation  but rather augmented 
lipid body formation (Fig. 5 A). In the presence of active, 
but not heat inactivated, superoxide dismutase plus catalase, 
oleic acid-stimulated lipid body numbers were greater than 
without these enzymes. In addition, the antioxidant, BHT, 
did  not  inhibit,  but  also  significantly  enhanced,  oleic 
acid-induced lipid body formation (Fig. 5 B). 
Oxidant stress of cells evoked by exposures to H202, su- 
peroxide anion or PMA-stimulated PMNs can deplete cellu- 
lar ATP (44), and cis-fatty acids can uncouple mitochondrial 
oxidative phosphorylation (3, 38).  cis-Unsaturated,  but not 
saturated, fatty acids have depleted cellular ATP and conse- 
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Figure 5.  The effects of superoxide dismutase (sod) and catalase 
(cat) (A) and the antioxidant BHT (B) on oleic acid-induced lipid 
body formation in PMNs. In A, PMNs were incubated for 30 min 
with and without 2.5 #M oleic acid alone or with active or heat- 
inactivated superoxide dismutase (5,000 U/ml) and catalase (25,000 
U/ml). Data are from one of three representative experiments with 
similar results. In B, PMNs were preincubated for 30 min at 37°C 
with the indicated concentrations of BHT and then washed and in- 
cubated for 30 min with oleic acid (OA). Comparable results were 
found when BHT was not washed from the ceils before oleic acid 
addition. Mean (+SEM) lipid bodies/PMN  were enumerated in 
25-50 PMNs. Statistical comparisons were by two-tailed student's 
t tests for comparisons between the same concentrations of oleic 
acid with and without BHT or sod/cat. (*)p < 0.05; (**)p < 0.001. 
quently inhibited 5-1ipoxygenase metabolism of arachidonic 
acid in alveolar macrophages (33). To determine if cis-fatty 
acid-stimulated induction of PMN lipid bodies was medi- 
ated by depletion of ATE several metabolic inhibitors were 
used to diminish ATP formation. Three agents which uncou- 
ple  mitochondrial  oxidative  phosphorylation,  2,4  DNP, 
oligomycin and valinomycin, in concentrations that diminish 
ATP in PMNs and other cells (2,  12, 24, 44; Roos, D., M. 
Reiss, A. J. M. Balm, A. M. Palache, E  H. Cambier, and 
J.  S.  van der Stijl-Neijenhuis.  1979.  Adv. Exp. Med.  Biol. 
121:29-36.), did not themselves elicit lipid body formation 
(data  not  shown).  Further,  the  numbers  of lipid  bodies 
elicited with low (1 #M) concentrations of oleic or palmitic 
acids  were  not  increased  to  levels  attained  with  higher 
(2.5-10  #M)  cis-fatty  acid  concentrations (Table I).  EM 
demonstrated that these oxidative phosphorylation inhibi- 
tors, while causing mild injury to PMNs, altered neither the 
ultrastructural morphology nor the numbers of lipid bodies 
(not shown). An inhibitor of glycolysis, 2-deoxyglucose, did 
Table I. Effects of  lnhibitors of  A TP Formation on 
Fatty Acid-induced PMN Lipid Body Formation 
Net lipid bodies/PMN 
Oleic  acid  Palmitic  acid 
2,4 DNP  0  M  5.6  +  1.0  -0.4  +  0.4 
10  -5 M  5.1  +  1.3  1.2  +  0.7 
10  -4 M  6.7  +  0.8  -0.5  +  0.4 
10  -3 M  8.6  +  0.9  1.0  +  0.6 
Oligomycin  0/xg/rrd  4.4  +  0.6  - 
25  /zg/ml  6.3  +  0.9  - 
Valinomycin  0  M  10.4  +  1.2  -1.6  +  0.3 
10  -8 M  9.4  +  1.1  0.2  5:0.8 
10  -7 M  5.8  +  1.0  -2.9  +  0.4 
10  -~ M  17.1  +  2.0  -2.0  +  0.2 
2  Deoxyglucose  0  M  19.2  +  2.1  -1.4  +  0.2 
10  -4 M  19.9  +  2.0  -1.4  +  0.4 
10  -3 M  3.7  +  1.0  -4.0  +  0.4 
10  -2 M  3.9  +  0.8  -1.9  +  0.1 
PMNs in 5.6 mM dextrose buffer were incubated with 1.0 and 5.0/zM oleic 
or palmitic acids and inhibitors as described in Materials and Methods. For 2 
deoxyglucose, which inhibited oleic acid-induced lipid body formation, results 
with 5 t~M fatty acids are presented. For other inhibitors, which did not pro- 
mote lipid body formation, presented results are with submaximal 1 #M fatty 
acid concentrations. Results, mean (+SEM)  lipid  bodies/PMN from 25-50 
PMNs minus lipid body numbers in control cells incubated with each inhibitor 
and 0.1% ethanol (between  2-5 lipid  bodies/PMN in different  experiments), 
are derived from separate experiments with each inhibitor. 
not promote oleic (or palmitic) acid-mediated lipid body 
formation, but instead significantly (p < 0.0001, t test) inhib- 
ited oleic acid-induced lipid body formation (Table I). 
cis-Fatty Acids and PKC Activation. Because fatty acids, 
especially cis-fatty acids, can activate PKC, other stimuli of 
PKC were evaluated. In contrast to the ineffectiveness of di- 
palmitin and diolein, the cell permeable, PKC-activating di- 
glyceride, OAG, was a potent stimulator of  lipid body forma- 
tion (Figs.  1 B and 6 A). The PKC-activating phorbol ester, 
PMA,  induced PMN lipid body formation within 30 min 
with maximal lipid body formation at 20 nM (Fig. 6 B). An- 
other phorbol ester, PDBu, at 2 and 20 nM, also elicited lipid 
body formation, with about 1/6th the molar potency of  PMA; 
whereas PDD, a phorbol not activating PKC, elicited no in- 
duction of lipid bodies in concentrations up to 200 nM (data 
not shown).  In the presence of superoxide dismutase plus 
catalase, greater numbers of lipid bodies were formed in re- 
sponse to PMA (Fig. 6 B) and PDBu, but not PDD (data not 
shown),  as  well  as  to  OAG,  arachidonic  acid  (data  not 
shown), and oleic acid (Fig. 5 A). 
PKC Inhibition and Fatty Acid-induced Lipid Body For- 
mation.  To further evaluate the role of PKC activation, the 
effects of several PKC inhibitors on fatty acid-induced lipid 
body formation were assessed. HMG, an effective inhibitor 
of PKC-mediated processes in human PMNs (25), potently 
inhibited lipid body formation induced by 2.5 #M concentra- 
tions of oleic acid, arachidonic acid, and OAG, 20 nM PMA 
(Fig. 7) and 20 nM PDBu (data not shown). HMG, at only 
3/~M, produced about 50 % inhibition of lipid body forma- 
tion induced by each of these stimuli. HMG, in the concen- 
trations used, inhibited cytosolic PKC activity of disrupted 
PMNs (Fig. 7  C).  Other PKC inhibitors were also tested. 
With 1/~M staurosporine, lipid body formation induced by 
2.5/~M arachidonic acid, oleic acid, and OAG was inhibited 
(mean +  SEM, n  -- 3) 39  +  21%, 48  +  10%, and 23  5: 
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Figure 6. Induction of lipid body formation by OAG (.4) or by PMA 
(B) alone or with superoxide dismutase/catalase (sod~cat) or oleic 
acid (OA). PMNs were incubated for 60 min with OAG or for 30 
min with PMA. Where indicated, superoxide dismutase (5,000 U/ 
ml) and catalase (25,000 U/ml) or 2.5 #M oleic acid were included 
with PMA. Mean net lipid bodies/PMN in 25-50 PMNs were cor- 
rected for lipid bodies (,'ol and 10/PMN, without and with superox- 
ide dismutase/catalase, respectively) in control PMNs incubated 
without stimuli. Data represent the means from triplicate experi- 
ments for PMA with superoxide dismutase/catalase and from du- 
plicate experiments for OAG, PMA, and PMA with oleic acid. 
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1%, respectively; and with 40 #M H-7 and the same three 
stimuli, mean inhibition (n =  2) was 52 +  18%, 91  +  7%, 
and 92 +  8%, respectively. H-7 at 25 and 50 #M and stauro- 
sporine at 50 #M inhibited PKC activity 24, 77, and 83 %, 
respectively, when assayed on disrupted PMNs. Sphingosine 
(5-25/~M)  could not  be evaluated  since  it was  toxic to 
PMNs, in accord with previous findings (26), under condi- 
tions used for lipid body induction (e.g., 30-45 min with ex- 
ogenous fatty acids but no BSA). The inhibition of cis-fatty 
acid-  and  diglyceride-stimulated lipid  body induction by 
staurosporine and H-7 supported the findings with HMG in- 
dicating that lipid body formation was mediated by PKC acti- 
vation. 
Discussion 
Although lipid bodies occur in a wide variety of cell types, 
mechanisms of formation and functions of these lipid-rich 
cytoplasmic inclusions have been uncertain. Normal blood 
PMNs have few lipid bodies, ,~0.7 per cell; but tissue, exu- 
date, and blood PMNs, when associated with inflammatory 
reactions, contain increased lipid body numbers (13, 23, 49). 
Lipid bodies  serve  as  nonmembrane  stores  of esterified 
arachidonate,  as  evidenced by autoradiography of PMNs 
(49), eosinophils (48), and other cells (18, 19, 23), and by 
lipid analyses of lipid bodies isolated from oosinophils (50). 
Lipid bodies, ultrastructurally identical to lipid bodies in 
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Figure 7. Inhibition by HMG of PMN lipid body formation induced 
by araehidonic acid, oleic acid, OAG, and PMA. PMNs were in- 
cubated with HMG at 37°C for 15 rnin and then with 2.5/~M ara- 
chidonic acid (AA) or oleic acid (OA) (A), or 2.5  #M OAG or 
20 nM PMA (B) for 30 rain. In each experiment mean net lipid 
bodies/PMN  in 50-75 cells were corrected for lipid bodies (be- 
tween 2-5/PMN) in PMNs incubated without stimuli. Results are 
means from four experiments, except values at 3 and 30/zM HMG 
are means from duplicate experiments. In C, PMN cytosolic PKC 
activity was assayed in the presence of concentrations of HMG; 
each value is the mean from triplicate experiments. 
PMNs in vivo, were elicited in PMNs incubated with arachi- 
donic and oleic acids (Fig. 3) (49). In evaluating mechanisms 
of lipid body formation in PMNs, our studies have indicated 
that activation of PKC, by these fatty acids or other stimuli, 
is involved in lipid body formation. 
While incubation of PMNs with exogenous fatty acids pro- 
vides a source of lipids for incorporation into newly forming 
lipid bodies, the structurally restricted capacities of different 
fatty acids and lipids to induce lipid bodies indicated that 
mechanisms other than simple availability of  lipid precursors 
were involved in lipid body formation. Palmitic acid, like 
other saturated fatty acids (eicosanoic, stearic, and myris- 
tic), failed to elicit lipid body formation; but [3H]-palmitic 
acid,  like  pH]-arachidortic and  [3H]-oleic acids,  is freely 
taken up by PMNs (34, 49) and incorporated into PMN lipid 
bodies (49).  Thus, while some lipids evaluated, including 
the diglycerides, dipalmitin and diolein, and the fatty acid 
methyl esters, are minimally permeant to intact cells, inabil- 
ity to be incorporated into cells or lipid bodies would not ac- 
count for the failure of saturated fatty acids to elicit lipid 
body induction, nor would differential incorporation explain 
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body-inducing activities  of various unsaturated  fatty acids 
(Fig. 4). 
The preferential  lipid body-inducing activities  of cis-un- 
saturated  fatty acids were not attributable to sequelae as- 
sociated with other metabolic effects of these fatty acids. In 
cells with active oxidative phosphorylation, including mac- 
rophages  (33)  and  lymphocytes (3),  cis-unsaturated  fatty 
acids  can  uncouple oxidative  phosphorylation  and  cause 
ATP depletion, which might impair fatty acid esterification 
(11). In PMNs three inhibitors  of oxidative phosphorylation 
did not elicit lipid body formation and did not augment fatty 
acid-induced lipid body formation  to levels attainable  with 
greater fatty acid concentrations.  Moreover, PMNs, in con- 
trast to other leukocytes, derive only 0.01-0.1% of their ATP 
from oxidative phosphorylation (24),  so inhibition of oxida- 
tive phosphorylation  would not account for cis-fatty  acid 
elicitation of PMN lipid bodies. Inhibition of glycolytic ATP 
generation  also did not promote, but rather significantly in- 
hibited,  fatty acid-induced lipid body formation (which was 
also inhibited at 4°C, data not shown). The lack of inhibition 
of oleic acid-induced lipid body formation  by BHT helped 
exclude  roles  for  free  radical  species,  products  of lipid 
peroxidation  derived from unsaturated  fatty acids (20),  or 
oxidant-induced  ATP depletion (44) in the genesis  of lipid 
bodies. Analogously,  since superoxide dismutase plus cata- 
lase did not inhibit  stimulated  lipid  body formation,  but 
rather augmented it (as considered more fully below), respi- 
ratory burst products  released extracellularly  from cis-fatty 
acid-stimulated PMNs (4, 5) were not involved in promot- 
ing lipid  body formation.  Thus,  lipid body formation  was 
temperature and energy dependent but not due to cis-fatty 
acid-induced  ATP  depletion  or cis-fatty  acid-elicited  ox- 
idants. 
Instead,  the  lipid  body-inducing  activities  of cis-fatty 
acids could be accounted for by their capacities to stimulate 
PKC (15, 30, 39, 40, 42), including human PMN PKC (29, 
43).  Since  PKC species,  including  those in human PMNs 
(29), can be activated by cis-unsaturated  fatty acids and not 
by trans- or saturated  fatty acids, such activation  would ex- 
plain the preferential activities of cis-unsaturated  fatty acids 
as inducers of lipid body formation.  In support of this mech- 
anism, lipid body formation was stimulated by other PKC ac- 
tivators, OAG, a cell permeable diglyceride well recognized 
to activate PKC (22, 32), PMA, and PDBu, both phorbol es- 
ter activators  of PKC (10), but not PDD, a phorbol without 
activity for PKC (10). Thus, nonfatty acid activators of PKC, 
as well as cis-fatty acids, were effective in stimulating PMN 
lipid body formation. 
The capacity of PKC inhibitors  to block lipid body forma- 
tion elicited both by cis-fatty  acids and by OAG and PMA 
further indicated  that PKC activation  was involved in lipid 
body formation.  The PKC inhibitor,  HMG, has been shown 
to inhibit PKC without inhibiting  cAMP-dependent  or Ca+/ 
calmodulin-dependent  kinases, to be noncytotoxic for PMNs 
at concentrations that inhibitedN-formyl-met-leu-phe  (flVILP) 
chemoattractant-  and phorbol ester-stimulated respiratory 
burst, and to inhibit specific phosphorylation in PMN cyto- 
plasts stimulated  with PDBu (25). In our assays, HMG was 
nontoxic to PMNs, elicited no lipid body formation by itself 
(data not shown), and inhibited PMN PKC. HMG inhibited 
lipid body formation induced by arachidonic  and oleic acids 
and by diglyceride and phorbol activators  of PKC.  HMG 
would be freely permeable within PMNs and able to act on 
intracellular,  possibly cytoplasmic,  PKC involved in forma- 
tion of cytoplasmic lipid bodies. Two other PKC inhibitors, 
H-7, and staurosporine,  also inhibited lipid body formation. 
That all three PKC inhibitors  blocked cis-fatty  acid-medi- 
ated lipid body formation excluded the possibility that PKC's 
role was solely as an intermediate  acting to increase intracel- 
lular-free fatty acids, which then were the primary promoters 
of lipid  body formation.  The formation  of lipid  bodies in 
PMNs, therefore, represents a response mediated by PKC as 
• evidenced by the abilities of several activators  of PKC (cis- 
fatty acids, diglyceride [OAG], and phorbol esters) to induce 
lipid body formation and by the actions of PKC inhibitors  to 
block lipid  body formation  induced by cis-fatty  acids and 
other PKC activators.  While the PKC isozymes involved in 
cis-fatty  acid- and diglyeeride-stimulated  lipid body forma- 
tion have not been defined in PMNs, in other cells subspecies 
of PKC can be differentially responsive to cis-fatty acid stim- 
ulation and, in the presence of these fatty acids,  may have 
differing requirements  for increased Ca  2÷ concentrations  for 
activation  (15, 30, 39, 40, 42). 
In addition  to stimulating  PKC, exogenous cis-fatty acids 
may contribute to lipid body formation  in other ways. As 
demonstrated with ultrastructural  autoradiography and lipid 
analyses,  exogenous  [3H]-arachidonate  and pH]-oleate (as 
well  as  [3H]-palmitate)  are  incorporated  into  leukocyte 
lipid  bodies as neutral  and phosphoglycerolipids  (48,  49, 
50). Lipids forming these inclusions  are not derived solely 
from exogenous fatty acids or diglycerides,  however, since 
phorbol esters can induce lipid body formation.  Phorbol es- 
ter stimulation  of PMNs has increased fatty acid incorpora- 
tion  into  phospholipids  (46),  promoted  accumulation  of 
phospholipid classes (41),  and stimulated  increases  in  1,2 
diacyl- and 1-O-alkyl-2-acyl-glycerols  (1, 16, 35, 47). Some 
of these endogenously formed lipids may be mobilized for 
inclusion  within  developing  cytoplasmic lipid bodies. 
The augmentation  of lipid body formation  by superoxide 
dismutase and catalase was notable,  since all  inducers  of 
lipid body formation  studied (arachidonic,  oleic, and other 
cis-fatty acids, OAG, and PMA) can elicit a respiratory burst 
in PMNs (4, 5, 22)• The diminished fatty acid-, but not phor- 
bol ester-, stimulated lipid body induction by  heat-inactivated 
superoxide dismutase and catalase was probably because of 
protein binding  of fatty acids by the quantifies  of enzymes 
used. The enhancing effects both of active, extracellular  su- 
peroxide dismutase plus catalase (despite protein binding of 
fatty acid stimuli) and of  BHT suggest that respiratory burst- 
derived oxidative products inhibit lipid body formation.  Ex- 
tracellular  oxidants  might  diminish  stimulating  fatty  acid 
concentrations  by oxidative alterations  of the cis-fatty acids 
(21), although  it is unclear if oxidants would similarly  de- 
grade OAG and PMA. Alternatively, oxidative products might 
act intracellularly  to inhibit  lipid body formation,  as sug- 
gested by the findings  with BHT-treated  PMNs that  were 
washed to remove free BHT. Whatever the mechanism,  su- 
peroxide anion, H202, or derivative compounds (e.g., HOCI, 
chloramines) appear to inhibit lipid body formation in PMNs. 
Conditions for inducing lipid body formation (i.e., 30-60- 
rain time course and specific diglyceride and cis-fatty  acid 
stimuli)  are similar  to conditions  used in studies of PMNs 
exposed to "priming" stimuli (6, 7, 8). Priming  stimuli have 
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tors (9, 22, 32), and 1-alkyl-2-acyl-diglycerides,  PKC inhibi- 
tors (7, 9, 14) (analogous to 1-O-alkyl-2-O-methyl-glyeerol, 
HMG [14, 25], used in this study). From our results, concen- 
trations of cell-permeant diacylglycerols  found effective for 
priming (,x,20 #M) (6, 7,  8) would also have induced lipid 
body formation.  Whether  1-alkyl-2-acyl-diglycerides  elicit 
lipid bodies is not known; but HMG, up to 100 t~M, did not 
stimulate lipid body formation.  While both diacyl- and al- 
kylacyl-glycerols  can prime PMNs,  significant differences 
were found between the two diglyceride classes in terms of 
their effects on fMLP-induced respiratory burst activity (7) 
and arachidonate metabolism (8).  Diacylglyceride  priming 
was specifically  effective in enabling PMNs, upon stimula- 
tion with fMLP, to form [3H]-arachidonate-derived eicosa- 
noids, whereas alkylacylglycerol priming inhibited such ei- 
cosanoid formation (8). Thus, the same priming diglycerides 
that enabled fMLP-induced eicosanoid formation in PMNs 
would also have elicited lipid bodies in PMNs. In conjunc- 
tion with our demonstration that lipid bodies can be a pre- 
dominant site of [3H]-arachidonate deposition within PMNs 
(48) and an intracellular localization of prostaglandin H syn- 
thase  (cyclooxygenase)  (WeUer,  P.  E,  and S.  W.  Ryeom, 
manuscript submitted for publication), lipid bodies may con- 
stitute a nonmembrane pool of esterified arachidonate from 
which  incorporated arachidonate  can be mobilized  for ei- 
cosanoid formation. 
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